3‐Mercaptopyruvate sulfurtransferase supports endothelial cell angiogenesis and bioenergetics. (4th March 2019)
- Record Type:
- Journal Article
- Title:
- 3‐Mercaptopyruvate sulfurtransferase supports endothelial cell angiogenesis and bioenergetics. (4th March 2019)
- Main Title:
- 3‐Mercaptopyruvate sulfurtransferase supports endothelial cell angiogenesis and bioenergetics
- Authors:
- Abdollahi Govar, Armita
Törő, Gábor
Szaniszlo, Peter
Pavlidou, Athanasia
Bibli, Sofia‐Iris
Thanki, Ketan
Resto, Vicente A.
Chao, Celia
Hellmich, Mark R.
Szabo, Csaba
Papapetropoulos, Andreas
Módis, Katalin - Abstract:
- Abstract : Background and Purpose: During angiogenesis, quiescent endothelial cells (ECs) are activated by various stimuli to form new blood vessels from pre‐existing ones in physiological and pathological conditions. Many research groups have shown that hydrogen sulfide (H2 S), the newest member of the gasotransmitter family, acts as a proangiogenic factor. To date, very little is known about the regulatory role of 3‐mercaptopyruvate sulfurtransferase (3‐MST), an important H2 S‐producing enzyme in ECs. The aim of our study was to explore the potential role of 3‐MST in human EC bioenergetics, metabolism, and angiogenesis. Experimental Approach: To assess in vitro angiogenic responses, we used EA.hy926 human vascular ECs subjected to shRNA‐mediated 3‐MST attenuation and pharmacological inhibition of proliferation, migration, and tube‐like network formation. To evaluate bioenergetic parameters, cell respiration, glycolysis, glucose uptake, and mitochondrial/glycolytic ATP production were measured. Finally, global metabolomic profiling was performed to determine the level of 669 metabolic compounds. Key Results: 3‐MST‐attenuated ECs subjected to shRNA or pharmacological inhibition of 3‐MST significantly reduced EC proliferation, migration, and tube‐like network formation. 3‐MST silencing also suppressed VEGF‐induced EC migration. From bioenergetic and metabolic standpoints, 3‐MST attenuation decreased mitochondrial respiration and mitochondrial ATP production, increased glucoseAbstract : Background and Purpose: During angiogenesis, quiescent endothelial cells (ECs) are activated by various stimuli to form new blood vessels from pre‐existing ones in physiological and pathological conditions. Many research groups have shown that hydrogen sulfide (H2 S), the newest member of the gasotransmitter family, acts as a proangiogenic factor. To date, very little is known about the regulatory role of 3‐mercaptopyruvate sulfurtransferase (3‐MST), an important H2 S‐producing enzyme in ECs. The aim of our study was to explore the potential role of 3‐MST in human EC bioenergetics, metabolism, and angiogenesis. Experimental Approach: To assess in vitro angiogenic responses, we used EA.hy926 human vascular ECs subjected to shRNA‐mediated 3‐MST attenuation and pharmacological inhibition of proliferation, migration, and tube‐like network formation. To evaluate bioenergetic parameters, cell respiration, glycolysis, glucose uptake, and mitochondrial/glycolytic ATP production were measured. Finally, global metabolomic profiling was performed to determine the level of 669 metabolic compounds. Key Results: 3‐MST‐attenuated ECs subjected to shRNA or pharmacological inhibition of 3‐MST significantly reduced EC proliferation, migration, and tube‐like network formation. 3‐MST silencing also suppressed VEGF‐induced EC migration. From bioenergetic and metabolic standpoints, 3‐MST attenuation decreased mitochondrial respiration and mitochondrial ATP production, increased glucose uptake, and perturbed the entire EC metabolome. Conclusion and Implications: 3‐MST regulates bioenergetics and morphological angiogenic functions in human ECs. The data presented in the current report support the view that 3‐MST pathway may be a potential candidate for therapeutic modulation of angiogenesis. Linked Articles: This article is part of a themed section on Hydrogen Sulfide in Biology & Medicine. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v177.4/issuetoc … (more)
- Is Part Of:
- British journal of pharmacology. Volume 177:Number 4(2020)
- Journal:
- British journal of pharmacology
- Issue:
- Volume 177:Number 4(2020)
- Issue Display:
- Volume 177, Issue 4 (2020)
- Year:
- 2020
- Volume:
- 177
- Issue:
- 4
- Issue Sort Value:
- 2020-0177-0004-0000
- Page Start:
- 866
- Page End:
- 883
- Publication Date:
- 2019-03-04
- Subjects:
- Pharmacology -- Periodicals
Chemotherapy -- Periodicals
Drug Therapy -- Periodicals
Pharmacology -- Periodicals
615.1 - Journal URLs:
- http://bibpurl.oclc.org/web/21844 ↗
http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1476-5381/issues ↗
http://www.pubmedcentral.nih.gov/tocrender.fcgi?journal=282&action=archive ↗
http://onlinelibrary.wiley.com/ ↗
http://www.nature.com/bjp/index.html ↗ - DOI:
- 10.1111/bph.14574 ↗
- Languages:
- English
- ISSNs:
- 0007-1188
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 2314.700000
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 22197.xml